FDA to discuss ALK-Abello's grass allergy tablet

ALK-Abello A/S (CSE:ALK-B) said FDA's Allergenic Products Advisory Committee will meet on Nov. 6 to discuss a BLA from partner Merck & Co. Inc. (NYSE:MRK) for grass Allergy Immunotherapy Tablet (AIT). Merck said it expects a decision on the application in 1Q14. The pharma has exclusive rights to develop and commercialize the tablet-based sublingual allergen immunotherapy in North America from ALK-Abello under a 2007 deal. ALK-Abello markets grass AIT as Grazax in Europe. ...